Skip to main content

Table 1 General and disease characteristics as well as endothelial function scores for patients in the cross-sectional study

From: The role of inflammation and cardiovascular disease risk on microvascular and macrovascular endothelial function in patients with rheumatoid arthritis: a cross-sectional and longitudinal study

  RA patients Number
General characteristics   
   Sex female n (%) 72 (73) 99
Disease characteristics   
   RF positive n (%) 70 (78) 90
   Disease duration (years) 11 ± 10 74
   ESR (mm/hr) 17.0 (8.8-28.3) 90
   CRP (mg/L) 5.0 (2.9-13.50) 93
   DAS28 3.6 ± 1.3 93
   HAQ 1.7 ± .87 95
RA medications   
   Methotrexate n (%) 60 (60) 99
   Prednisolone n (%) 22 (22) 99
   NSAIDS n (%) 18 (18) 99
   Cyclooxygenase II inhibitors n (%) 11 (11) 99
   Anti-TNF-α therapy n (%) 11 (11) 99
CVD medications   
   Antihypertensive n (%) 25 (25) 99
   Antihypercholesterolemic n (%) 12 (12) 99
   Beta-blocker n (%) 7 (7) 99
   Calcium channel blocker n (%) 5 (5) 99
Microvascular function   
Endothelium-dependent (ACh%) 236 (152-407) 94
Endothelium-independent (SNP%) 261 (181-384) 94
Macrovascular function   
Endothelium-dependent (FMD%) 9.5 (4.8-13.5) 96
Endothelium-independent (GTN%) 24.0 (16.3-30.4) 93
  1. Results are expressed as number (percentage), mean ± SD, or median (25th to 75th) percentile, as appropriate. Ach, acetylcholine; CRP, C-reactive protein; CVD, cardiovascular disease; DAS28, disease activity score in 28 joints; ESR, erythrocyte sedimentation rate; FMD, flow-mediated dilatation; GTN, glyceryl trinitrate; HAQ, Health Assessment Questionnaire, NSAID, nonsteroidal antiinflammatory drug; RA, rheumatoid arthritis; RF, rheumatoid factor; TNF, tumor necrosis factor; SNP, sodium nitroprusside.